Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
The United States autoinjector market was valued at USD 0.74 Billion in 2025, driven by the regulatory support and technological advancements in the region. The market is anticipated to grow at a CAGR of 14.20% during the forecast period of 2026-2035, with the values likely to reach USD 2.79 Billion by 2035. The market is driven by growing demand for self-administered therapies, advancements in smart autoinjectors, and increased adoption in home healthcare due to rising chronic disease prevalence.
Compound Annual Growth Rate
14.2%
Value in USD Billion
2026-2035
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Autoinjector devices are prefilled, self-administering drug delivery systems designed for rapid, accurate, and convenient injection without professional assistance. The market for autoinjectors in the United States is experiencing significant growth, driven by rising chronic disease prevalence, increasing self-medication trends, and technological advancements enhancing patient compliance and safety.
Next-Generation Testing Technology Set to Augment Market Demand
Integrating advanced testing systems will enhance the reliability and quality assurance of autoinjector devices. For instance, in June 2024, Instron launched its next-generation autoinjector testing system, enabling comprehensive functionality testing on a single platform. By streamlining validation and production transfer processes, this innovation supports efficiency and product safety, ultimately accelerating market growth.
Some of the notable trends in the market include expanding regulatory approvals for injectable therapies and increasing government initiatives focused on emergency preparedness and access to critical self-injection treatments.
Expanding regulatory approvals for treatments represent a significant trend in the autoinjector devices market. In August 2024, the U.S. FDA approved Zurnai, the first nalmefene hydrochloride auto-injector for emergency opioid overdose treatment. This milestone, in alignment with the FDA’s overdose prevention framework, is anticipated to foster innovation and accelerate market growth.
A growing trend in the market is the increased investment in emergency preparedness and public health response. In April 2025, Barda’s funding to Kaléo for developing 2-PAM autoinjectors highlighted the government’s commitment to enhancing rapid-response capabilities. Such initiatives are expected to drive market growth by advancing autoinjector innovation and expanding strategic stockpiles.
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Type
Market Breakup by Volume
Market Breakup by Technology
Market Breakup by Route of Administration
Market Breakup by Application
Market Breakup by End User
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Segmentation Based on Application to Witness Substantial Growth
Based on the type, the market is segmented into disposable and reusable. The disposable segment is anticipated to have a substantial share of the market, driven by increasing demand for hygienic and single-use medical products across healthcare settings. Enhanced infection control protocols, cost-effectiveness in bulk procurement, and minimal maintenance requirements contribute to its widespread adoption. Additionally, the growing preference in outpatient and homecare environments further strengthens the segment's projected market dominance.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The autoinjector devices market in the United States demonstrates strong regional performance, with leading growth observed in the Mideast and Southeast regions. These areas benefit from advanced healthcare infrastructure, high chronic disease prevalence, and increasing patient awareness. Additionally, the Southwest regions contribute significantly, driven by rising demand for self-administration solutions and supportive healthcare policies.
The key features of the market report comprise patent analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Eli Lilly and Company, founded in 1876 and headquartered in Indianapolis, Indiana, plays a pivotal role in the market. In August 2024, the company expanded access to Zepbound (tirzepatide) by introducing single-dose vials and autoinjector pens for adults with obesity. This launch enhances treatment accessibility and supports patients with self-administered, subcutaneous weight management solutions.Teva Pharmaceuticals: Teva Pharmaceuticals plays a significant role in the autoinjector market. It was established in 1901 and is headquartered in Tel Aviv, Israel. The company offers Epinephrine injection, USP (auto-injector), a generic equivalent to EpiPen and EpiPen Jr. These pre-filled, single-dose autoinjectors are used in the emergency treatment of allergic reactions, highlighting Teva’s commitment to accessible, life-saving therapies.
Ypsomed, headquartered in Burgdorf, Switzerland, was established in 1984 and is actively contributing to the autoinjector devices market. The company’s innovative product, YpsoMate On, is a pre-filled autoinjector featuring integrated connectivity that logs injections automatically and enhances therapy adherence. Recognized with the Pharmapack 2022 Innovation Award, it supports digital therapy management with a sustainable, user-friendly design.
SHL Medical, established in 1989, is headquartered in Switzerland. The company specializes in the development, manufacturing, and assembly of drug delivery devices, including autoinjectors. In 2022, SHL Medical expanded into the U.S. market with a new facility in North Charleston, South Carolina. Their product lineup includes the Molly autoinjectors, designed for self-injection systems, crucial for treating chronic diseases. This move enhances their ability to meet growing demand in the U.S. autoinjector devices market.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other key players in the market include Pfizer, Inc., Amgen, Sanofi, Mylan N.V., and Biogen.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Type |
|
| Breakup by Volume |
|
| Breakup by Technology |
|
| Breakup by Route of Administration |
|
| Breakup by Application |
|
| Breakup by End User |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.